中外医学研究
中外醫學研究
중외의학연구
CHINESE AND FOREIGN MEDICAL RESEARCH
2013年
33期
15-15,16
,共2页
许爱琴%尤加永%赵长银
許愛琴%尤加永%趙長銀
허애금%우가영%조장은
阿立哌唑%齐拉西酮%女性%精神分裂症
阿立哌唑%齊拉西酮%女性%精神分裂癥
아립고서%제랍서동%녀성%정신분렬증
Aripiprazole%Ziprasidone%Female%Schizophrenia
目的:评价齐拉西酮与阿立哌唑治疗女性首发精神分裂症的疗效与不良反应。方法:31例符合CCMD-3精神分裂症诊断标准的女性首发患者随机分为阿立哌唑(博思清)组(36例)和齐拉西酮(思贝格)组(35例),采用阳性症状与阴性症状量表(positive symptoms and negative symptoms scale,PANSS)评定疗效,副反应量表(treatment Emergent Symptom Scale,TESS)评价药物安全性。结果:两组患者治疗前及治疗后2、4、8 PANSS评分差异无显著性(P>0.05),两组均无严重不良反应。结论:阿立哌唑和齐拉西酮治疗女性首发精神分裂症有效,且不良反应少。
目的:評價齊拉西酮與阿立哌唑治療女性首髮精神分裂癥的療效與不良反應。方法:31例符閤CCMD-3精神分裂癥診斷標準的女性首髮患者隨機分為阿立哌唑(博思清)組(36例)和齊拉西酮(思貝格)組(35例),採用暘性癥狀與陰性癥狀量錶(positive symptoms and negative symptoms scale,PANSS)評定療效,副反應量錶(treatment Emergent Symptom Scale,TESS)評價藥物安全性。結果:兩組患者治療前及治療後2、4、8 PANSS評分差異無顯著性(P>0.05),兩組均無嚴重不良反應。結論:阿立哌唑和齊拉西酮治療女性首髮精神分裂癥有效,且不良反應少。
목적:평개제랍서동여아립고서치료녀성수발정신분렬증적료효여불량반응。방법:31례부합CCMD-3정신분렬증진단표준적녀성수발환자수궤분위아립고서(박사청)조(36례)화제랍서동(사패격)조(35례),채용양성증상여음성증상량표(positive symptoms and negative symptoms scale,PANSS)평정료효,부반응량표(treatment Emergent Symptom Scale,TESS)평개약물안전성。결과:량조환자치료전급치료후2、4、8 PANSS평분차이무현저성(P>0.05),량조균무엄중불량반응。결론:아립고서화제랍서동치료녀성수발정신분렬증유효,차불량반응소。
Objective:To evaluate the efficacy and adverse reactions of aripiprazole and ziprasidone in female first-onset schizophrenia.Method:31 female first-onset schizophrenia patients met the CCMD-3 diagnosis of schizophrenia were randomly assigned to aripiprazole group (36 patients) and ziprasidone group (35 cases). Positive symptoms and negative syndrome scale(PANSS) and treatment Emergent Symptom Scale(TESS) were used to evaluate the efficacy and safety.Result:There was no significant difference in PANSS scores(P>0.05) before and after 2,4,8 week’treatment between two groups. The two groups had no serious adverse reactions.Conclusion:Aripiprazole and ziprasidone were effective and less adverse reactions in treatment of female first-onset schizophrenia.